Non-Hodgkin's B-cell Lymphoma Clinical Trial
Official title:
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL
This is a single-arm, open label, dose escalation, phase I study of C-CAR039 in adults with relapsed/refractory B-cell Non-Hodgkin's Lymphoma.
This is a single-arm, open label, "3+3" dose escalation, phase I study to evaluate the safety and preliminary efficacy of C-CAR039 in adults with relapsed/refractory B-cell Non-Hodgkin's Lymphoma. 10 patients are planned to be enrolled. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of C-CAR039. Following manufacture of the drug product, subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide prior to C-CAR039 infusion. All subjects who have received C-CAR039 infusion will be followed for up to 24 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04317885 -
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT04696432 -
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT02361346 -
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04655677 -
A Study of EXP039 Treatment in Subjects With r/r NHL Subjects
|
Phase 1 | |
| Suspended |
NCT04148742 -
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03000192 -
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
|
||
| No longer available |
NCT02715843 -
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
|